MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults

OBJECTIVE: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth hormone (MOD-4023) is being developed as a once-weekly dosing regimen in patients with GH deficiency (GHD). This study’s objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Strasburger, Christian J, Vanuga, Peter, Payer, Juraj, Pfeifer, Marija, Popovic, Vera, Bajnok, László, Góth, Miklós, Olšovská, Veˇra, Trejbalová, L‘udmila, Vadasz, Janos, Fima, Eyal, Koren, Ronit, Amitzi, Leanne, Bidlingmaier, Martin, Hershkovitz, Oren, Hart, Gili, Biller, Beverly M K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292974/
https://www.ncbi.nlm.nih.gov/pubmed/27932411
http://dx.doi.org/10.1530/EJE-16-0748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292974/
https://www.ncbi.nlm.nih.gov/pubmed/27932411
http://dx.doi.org/10.1530/EJE-16-0748

Ejemplares similares